Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy

Chulalongkorn University

Status and phase

Completed

Phase 3

Conditions

Gynecologic Cancer

Treatments

Drug: Intravenous iron

Study type

Interventional

Funder types

Other

Identifiers

NCT01435200

IV iron 2

Details and patient eligibility

About

Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?

Full description

Anemia is a common condition during chemotherapy administration. Treatment options usually include oral iron supplementation and blood transfusion. However, oral iron has gastrointestinal side effects, which affects patient compliance, and only a small amount of oral iron can be absorbed from the gastrointestinal tract. Intravenous iron may overcome a block of iron absorption and iron recycling induced by hepcidin. Therefore, it may increase hemoglobin level and reduced blood transfusion in cancer patients receiving chemotherapy.

Enrollment

64 patients

Sex

Female

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 20-70 years
Good performance status (Zubrod score < 2)
No serious underlying disease
Normal renal function test
Normal liver function test
Platinum based chemotherapy is the first line regimen
No prior or receiving radiotherapy

Exclusion criteria

Iron hypersensitivity
Underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia
Progressive disease
Bone marrow metastasis